A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus‐associated cancers

A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus‐associated cancers

M Reuschenbach, C Pauligk, J Karbach, MR Rafiyan… - Cancer, 2016 - Wiley Online Library

... MATERIALS AND METHODS Investigational Agent The P16_37-63 peptide was synthesized,
formulated, packed, and distributed in accordance with current GMP protocols by Bachem (Weil
am Rhein, Germany). Mon- tanide ISA-51 VG was supplied by SEPPIC GmbH. ...

Peptide synthesis, peptide modification and peptide library synthesis, please contact:

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com